Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

  • Merck & Co Inc (NYSE:MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
  • The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. 
  • After a planned interim analysis, Merck is discontinuing the study following an independent Data Monitoring Committee (DMC) recommendation. 
  • At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS) compared to the control arm of either abiraterone acetate or enzalutamide. 
  • Related: AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer.
  • The trial's other dual primary endpoint, radiographic progression-free survival (rPFS), was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. 
  • Merck has an extensive clinical development program in prostate cancer, evaluating Keytruda as monotherapy and in combination with Lynparza and other anti-cancer therapies. 
  • Price Action: MRK shares are down 0.14% at $77.67, and AZN shares are up 0.68% at $60.80 during the premarket session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.